Patents Represented by Attorney, Agent or Law Firm Mark R. Daniel
  • (Bicyclic-hetero-arylmethoxy)indoles as inhibitors of leukotriene biosynthesis
    Patent number: 5308850
    Abstract: Compounds having the formula I: ##STR1## are inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating diarrhea, hypertension, angina, platelet aggregation, cerebral spasm, premature labor, spontaneous abortion, dysmenorrhea, and migraine.
    Type: Grant
    Filed: September 25, 1992
    Date of Patent: May 3, 1994
    Assignee: Merck Frosst Canada, Inc.
    Inventors: John W. Gillard, John H. Hutchinson, Richard Frenette, Michel Therien
  • Quinazolinones
    Patent number: 5308846
    Abstract: Substituted quinazolinones and pyridopyrimidines of structural formula 1 ##STR1## are angiotensin II antagonists useful in the treatment of disorders related to the renin-angiotensin system (RAS) such as hypertension, congestive heart failure, ocular hypertension and certain CNS disorders.
    Type: Grant
    Filed: July 22, 1993
    Date of Patent: May 3, 1994
    Assignees: Merck & Co., Inc., E. I. Du Pont de Nemours and Co.
    Inventors: Eric E. Allen, Richard E. Olson
  • Tricyclic derivatives of the thienodiazocine and thienothiadiazocine classes of compounds
    Patent number: 5308842
    Abstract: Conformationally constrained tricyclic derivatives of the thienodiazocine and thienothiadiazocine classes of compounds and ring homologs thereof are topically effective carbonic anhydrase inhibitors useful in the treatment of ocular hypertension and glaucoma associated therewith.
    Type: Grant
    Filed: May 10, 1993
    Date of Patent: May 3, 1994
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, Gerald S. Ponticello
  • Heteroarylnaphthalenes as inhibitors of leukotriene biosynthesis
    Patent number: 5308852
    Abstract: Compounds having the formula I: ##STR1## are inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis and allograft rejection and in preventing the formation of atherosclerotic plaques.
    Type: Grant
    Filed: August 27, 1992
    Date of Patent: May 3, 1994
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Yves Girard, Daniel Delorme, Rejean Fortin, Daniel Dube, Pierre Hamel, Carol Lepine, Yves Ducharme
  • Methods of achieving antileukemia activity using 16-membered-macrolide-type compounds
    Patent number: 5306716
    Abstract: Inhibition of renal cancer, melanoma, colon cancer, lung cancer and leukemia cells by administration of compounds from the bafilomycin and hygrolidin groups of compounds.
    Type: Grant
    Filed: March 20, 1992
    Date of Patent: April 26, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Tom G. Holt, Richard L. Monaghan
  • Compositions containing a 4-quinolone derivative complexed with a divalent metal ion
    Patent number: 5304559
    Abstract: The present invention concerns a fluid pharmaceutical composition intended to be brought into contact with a physiological fluid, characterized in that it contains, as active principle, at least one 4-quinolone derivative complexed with a divalent metal ion selected from Cu.sup.++, Zn.sup.++ and Mg.sup.++, the said complex being in the form of particles of a size compatible with parenteral or ophthalmic administration, in suspension in a fluid dispersant and not being subject to a crystalline growth phenomenon during storage of the said composition; the invention also provides a process for preparing a pharmaceutical composition of this type.
    Type: Grant
    Filed: August 9, 1991
    Date of Patent: April 19, 1994
    Assignee: Laboratoires Merck Sharp & Dohme Chibret
    Inventor: Annouk Rozier
  • Antibiotic producing microorganism
    Patent number: 5304485
    Abstract: An organism of the Sporormiella species produces a compound having the formula ##STR1## which is useful. The compound is useful as an antifungal agent.
    Type: Grant
    Filed: October 19, 1992
    Date of Patent: April 19, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Gerald F. Bills, Fernando Pelaez
  • Farnesyl pyrophosphate analogs
    Patent number: 5298655
    Abstract: The present invention is directed to farnesyl pyrophosphate analogs which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention, and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.
    Type: Grant
    Filed: September 27, 1991
    Date of Patent: March 29, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Neville J. Anthony, Ta-Jyh Lee, Robert L. Smith, Gerald E. Stokker
  • Intermediates for preparing cationic-2-heteroaryl-phenyl-carbapenem antibacterial agents
    Patent number: 5292879
    Abstract: Carbapenem compounds of the formula ##STR1## are useful intermediates for preparing antibacterial agents.
    Type: Grant
    Filed: August 28, 1992
    Date of Patent: March 8, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Frank DiNinno, Ravindra N. Guthikonda, Susan M. Schmitt
  • Macrocycles incorporating quinazolinones
    Patent number: 5292741
    Abstract: Macrocyclic compounds of general Structure I: ##STR1## Wherein M is C or N are angiotensin II receptor (A-II) antagonists useful in the treatment of certain cardiovascular dysfunctions and ocular hypertension.
    Type: Grant
    Filed: August 18, 1992
    Date of Patent: March 8, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Stephen E. deLaszlo, Tomasz Glinka, Robert B. Nachbar, Eric E. Allen, Kristine Prendergast
  • (hetero-arylmethoxy)indoles as inhibitors of leukotriene biosynthesis
    Patent number: 5290798
    Abstract: Compounds having the formula I: ##STR1## are inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating diarrhea, hypertension, angina, platelet aggregation, cerebral spasm, premature labor, spontaneous abortion, dysmenorrhea, and migraine.
    Type: Grant
    Filed: September 25, 1992
    Date of Patent: March 1, 1994
    Assignee: Merck Frosst Canada, Inc.
    Inventors: John W. Gillard, John H. Hutchinson, Michel Therien
  • Anthelmintic milbemycin analogs of novel microorganisms
    Patent number: 5290804
    Abstract: There is disclosed a series of macrolides isolated from the fermentation broth of microorganisms identified as MA-6825, MA-6864 and MA-6865. The structure of the novel compounds isolated from the microorganisms is presented based upon analytical studies. The compounds are highly potent antiparasitic, insecticidal, and anthelmintic agents and are related to the class of macrolides known as milbemycins. Compositions for such uses are also disclosed.
    Type: Grant
    Filed: April 13, 1992
    Date of Patent: March 1, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Robert T. Goegelman, Elvira Munguira, Maria T. Diez Matas, Ruth S. Sykes, Yu L. Kong, Jerrold M. Liesch, Gregory L. Helms, E. Tracy Turner Jones
  • Substituted 1,2,4-triazoles bearing acidic functional groups as angiotensin II antagonists
    Patent number: 5281614
    Abstract: Novel substituted triazolinone, triazolinethione, and triazolinimine compounds of the formula I are useful as angiotensin II antagonists.
    Type: Grant
    Filed: November 2, 1992
    Date of Patent: January 25, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Wallace T. Ashton, Prasun K. Chakravarty, Linda L. Chang, William J. Greenlee, Dooseop Kim, Nathan B. Mantlo, Arthur A. Patchett
  • Pyranylphenyl hydroxyalkylnaphthoic acids as inhibitors of leukotriene biosynthesis
    Patent number: 5281720
    Abstract: Compounds having the formula I: ##STR1## are inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis and allograft rejection and in preventing the formation of atherosclerotic plaques.
    Type: Grant
    Filed: October 26, 1992
    Date of Patent: January 25, 1994
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Robert N. Young, Yves Girard, John W. Gillard, Laird A. Trimble, John Scheigetz, James A. Yergey, Yves Ducharme, Deborah A. Nicoll-Griffith, John H. Hutchinson
  • Heterobicyclic sulfonamides
    Patent number: 5276025
    Abstract: Compounds of general formula: ##STR1## are topically effective carbonic anhydrase inhibitors useful in the treatment of ocular hypertension and related disorders such as glaucoma.
    Type: Grant
    Filed: September 9, 1992
    Date of Patent: January 4, 1994
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, Jacob M. Hoffman, Jr., James H. Jones, Clarence S. Rooney, Anthony M. Smith
  • Substituted hexahydrobenzopyran derivatives as angiotensin II antagonists
    Patent number: 5276054
    Abstract: Substituted hexahydrobenzopyran derivatives of the Formulae A, B, or C are useful as angiotensin II antagonists: ##STR1##
    Type: Grant
    Filed: October 16, 1992
    Date of Patent: January 4, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Maria T. Diez, Michael A. Goetz, Robert A. Giacobbe, Otto D. Hensens, Leeyan Huang, Isabel Martin, E. Tracy T. Jones, Siobhan Stevens-Miles, Yu L. Kong
  • Bicyclic-azaarylmethoxy) indoles as inhibitors of leukotriene biosynthesis
    Patent number: 5273980
    Abstract: Compounds having the formula I: ##STR1## are inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating diarrhea, hypertension, angina, platelet aggregation, cerebral spasm, premature labor, spontaneous abortion, dysmenorrhea, and migraine.
    Type: Grant
    Filed: September 25, 1992
    Date of Patent: December 28, 1993
    Assignee: Merck Frosst Canada Inc.
    Inventors: Richard Frenette, Michel Therien, John H. Hutchinson
  • Hydrazine synthesis
    Patent number: 5274096
    Abstract: An improved synthesis is described for producing a quinolinylmethoxyphenyl hydrazine which is an intermediate in the preparation of quinolinylmethoxyindoles useful as inhibitors of leukotriene biosynthesis. The improved process eliminates two isolation steps and yields a product of high purity.
    Type: Grant
    Filed: March 17, 1992
    Date of Patent: December 28, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Joseph F. Payack, Dalian Zhao
  • Adjuncts in cancer chemotherapy
    Patent number: 5272159
    Abstract: Various cyproheptadine derivatives sensitize multidrug resistant cells to certain chemotherapeutic agents. As such, these cyproheptadine derivatives are useful as adjuncts in the reversal of multidrug resistance in mammalian tumor cells either as compounds, pharmaceutically acceptable salts, or pharmaceutical composition ingredients in combination with anticancer chemotherapeutic agents or compounds.
    Type: Grant
    Filed: December 17, 1991
    Date of Patent: December 21, 1993
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, David C. Remy
  • (Quinolin-2-ylmethoxy)indoles as inhibitors of the biosynthesis of leukotrienes
    Patent number: 5272145
    Abstract: Compounds having the formula I: ##STR1## are inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating diarrhea, hypertension, angina, platelet aggregation, cerebral spasm, premature labor, spontaneous abortion, dysmenorrhea, and migraine.
    Type: Grant
    Filed: December 14, 1992
    Date of Patent: December 21, 1993
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Petpiboon Prasit, Rejean Fortin, John H. Hutchinson, Michel L. Belley, Serge Leger, Richard Frenette, John Gillard